Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

Executive Summary

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

You may also be interested in...



Lack Of Comparative Trials Stymied BMS’s EU Filings For Opdivo In Colorectal, Liver Cancers

Bristol-Myers Squibb’s decision to withdraw its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC) follows a similar move for liver cancer last year. The company now seems to be more interested in pursuing the product’s use in combination with Yervoy and Mekinist in mCRC.

Opdivo’s EU Colorectal Cancer Setback ‘More Than Offset’ By Potential Gains In Combination

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Don't Lose Track: Review And Approval News On Opdivo, Kalydeco And More

US FDA had a busy week. Here's some bullet points of product development events you may have missed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099250

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel